Chemical Namemeropenem and vaborbactam
Dosage FormInjectable (intravenous; 2 g/vial (1 g meropenem (equivalent to 1.14 g meropenem trihydrate) and 1 g vaborbactam))
Drug ClassInhibitors
CompanyRempex Pharmaceuticals
Approval Year2017


  • Vabomere is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vabomere (meropenem and vaborbactam) prescribing information.2019Melinta Therapeutics